And people say that public ownership is "less efficient" than private industry, and less efficient than regulated private industry.
Well.. I don't buy it. Access to drugs and efficient pricing and rationing (because that is what it is) is not working well. It's a massively distorted market.
The public good here would be better served by another model.
Even the "we need these prices to recover our massive sunk costs" part of the argument is bogus. Much good drug design and research is done on the tertiary education and research budget worldwide.
There is absolutely no single-process need to do drug IPR based models, the profit motive is not the only model.
I look to the modern mRNA drug emergence to lead to radical shake up in the cost of production of novel treatments. We're seeing some signs of this, along with other changes in drug models: injectable hypertension treatment is in test. Imagine the impact on the cost basis of a pill-per-day model!
Well.. I don't buy it. Access to drugs and efficient pricing and rationing (because that is what it is) is not working well. It's a massively distorted market.
The public good here would be better served by another model.
Even the "we need these prices to recover our massive sunk costs" part of the argument is bogus. Much good drug design and research is done on the tertiary education and research budget worldwide.
There is absolutely no single-process need to do drug IPR based models, the profit motive is not the only model.
I look to the modern mRNA drug emergence to lead to radical shake up in the cost of production of novel treatments. We're seeing some signs of this, along with other changes in drug models: injectable hypertension treatment is in test. Imagine the impact on the cost basis of a pill-per-day model!